<DOC>
	<DOC>NCT02466867</DOC>
	<brief_summary>This is an open label, multi-center, multi-application pharmacokinetic study in pediatric subjects with tinea corporis.</brief_summary>
	<brief_title>An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis</brief_title>
	<detailed_description />
	<mesh_term>Tinea</mesh_term>
	<mesh_term>Naftifine</mesh_term>
	<criteria>Male or females 2 to 11 years, 11 months of any race. Females of child producing age (started menarche) must have a negative urine pregnancy test. Presence of tinea corporis characterized by clinical evidence of a tinea infection at multiple sites covering a total of at least 1% body surface area. KOH positive and culture positive baseline skin scrapings obtained from the site most severely affected of the overall severity. Subjects must be in good health and free from clinically significant disease that might interfere with the study evaluations. Tinea infection of the scalp, face, groin, and/or feet. A lifethreatening condition (ex. autoimmune deficiency syndrome, cancer) within the last 6 months Subject with abnormal findingsphysically or laboratory that considered by the investigator to be clinically important and indicative of conditions that might complicate interpretation of study results. Subjects with a known hypersensitivity or other contradictions to study medications or their components.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Ringworm</keyword>
</DOC>